Cassava Sciences Inc
Company Profile
Business description
Cassava Sciences Inc is a clinical-stage biotechnology company engaged in developing a scientific approach for the treatment and detection of Alzheimer's disease. Its therapeutic product candidate is called simufilam, and it is a novel treatment for Alzheimer's disease; and investigational diagnostic product candidate is called SavaDx and it is a novel way to detect the presence of Alzheimer's disease from a small sample of blood, possibly years before the overt appearance of clinical symptoms. It is currently conducting two randomized placebo-controlled Phase 3 clinical trials of oral simufilam in patients with Alzheimer’s disease dementia. It has one business segment: the development of novel drugs and diagnostics.
Contact
6801 N. Capital of Texas Highway
Suite 300, Building 1
AustinTX78731
USAT: +1 512 501-2444
Sector
Healthcare
Stock type
Defensive
Industry
Biotechnology
Fiscal Year End
31 December 2025
Employees
30
Stocks News & Analysis
stocks
The ‘other’ AI chip behemoth that might just be getting started
stocks
Why ANZ changes aren’t just about cutting costs
stocks
Strong finish to the year for overvalued ASX share
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 9,095.20 | 28.80 | 0.32% |
| CAC 40 | 7,761.32 | 11.93 | 0.15% |
| DAX 40 | 23,632.95 | 85.50 | -0.36% |
| Dow JONES (US) | 45,490.92 | 220.42 | -0.48% |
| FTSE 100 | 9,225.39 | 17.14 | -0.19% |
| HKSE | 26,200.26 | 262.13 | 1.01% |
| NASDAQ | 21,886.06 | 6.57 | 0.03% |
| Nikkei 225 | 43,837.67 | 378.38 | 0.87% |
| NZX 50 Index | 13,254.23 | 22.01 | -0.17% |
| S&P 500 | 6,532.04 | 19.43 | 0.30% |
| S&P/ASX 200 | 8,830.40 | 40.00 | 0.46% |
| SSE Composite Index | 3,812.22 | 4.93 | 0.13% |